TG

Tredegar Corporation 2008 Annual Report (10-K) Summary

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2008. Tredegar Corporation operates through two primary segments: Film Products (plastic films, elastics, and laminates for personal care and packaging) and Aluminum Extrusions (soft-alloy aluminum extrusions for construction and industrial markets). The company sold its Canadian aluminum extrusions business on February 12, 2008, which is reported as discontinued operations. The company is headquartered in Richmond, Virginia, and employs approximately 2,200 people in continuing operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Consolidated sales decreased 4.2% to $883.9 million. Film Products sales dropped 1.5% due to lower volume from competitive pressures, while Aluminum Extrusions sales fell 8.5% due to a significant decline in construction-related demand.
• Profitability: Income from continuing operations decreased 15.2% to $29.6 million. This was driven by lower volumes in both segments and $12.0 million in pre-tax charges for asset impairments and restructuring costs, partially offset by a $5.6 million unrealized gain on a drug delivery investment.
• Discontinued Operations: The sale of the Canadian aluminum extrusions business resulted in a net loss of $0.7 million in 2008, compared to a loss of $19.7 million in 2007 (which included significant impairment charges).
• Liquidity Improvement: The company improved its balance sheet significantly, moving from net debt of $33.8 million in 2007 to a net cash position of $23.3 million in 2008, aided by proceeds from the Canadian business sale and strong operating cash flows.
• Restructuring: Film Products reduced its workforce by approximately 6% (90 employees) in Q1 2008, with expected annualized savings of $4.2 million.

Guidance, Outlook, and Risks

• Outlook: Management expects volume and operating profits in both segments to continue being adversely impacted by competitive pressures and the global economic downturn. Capital expenditures are projected to be approximately $46 million in 2009 ($22 million for Film Products and $24 million for Aluminum Extrusions).
• Customer Concentration: The company remains highly dependent on The Procter & Gamble Company (P&G), which accounted for approximately 33% of consolidated net sales in 2008. Loss of this customer would have a material adverse effect.
• Market Risks: Significant exposure to volatility in raw material costs (resin, aluminum, natural gas) and energy prices. The company utilizes pass-through provisions but cannot guarantee full offset of cost increases.
• Goodwill Impairment Risk: The fair value of the Aluminum Extrusions reporting unit exceeded its carrying value by only approximately 12% at year-end. Management notes a "reasonably possible chance" that a goodwill impairment could be triggered in the future if business conditions deteriorate further.
• Investment Risk: The company holds high-risk investments, including a $10 million stake in Harbinger Capital Partners and a $13.1 million investment in a privately held drug delivery company (accounted for at fair value).

Investor Verification Checklist

• Customer Concentration: Verify the stability of the relationship with P&G and any potential shifts in their sourcing strategies.
• Goodwill Valuation: Monitor the Aluminum Extrusions segment closely for signs of further volume decline that could trigger a goodwill impairment charge (potential write-off of $30.6 million).
• Raw Material Pass-Through: Assess the company's ability to pass through rising resin and aluminum costs to customers in a deflationary or competitive pricing environment.
• Discontinued Operations: Confirm that all tax benefits and liabilities related to the Canadian business sale have been fully realized and accounted for.
• Investment Volatility: Review the valuation methodology for the drug delivery investment, which relies on Level 3 inputs and future financing rounds.